Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Dow
Cantor Fitzgerald
McKinsey
QuintilesIMS
Chinese Patent Office
Queensland Health
Medtronic
Merck

Generated: October 20, 2018

DrugPatentWatch Database Preview

CAPRELSA Drug Profile

« Back to Dashboard

Which patents cover Caprelsa, and when can generic versions of Caprelsa launch?

Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in CAPRELSA is vandetanib. Two suppliers are listed for this compound. Additional details are available on the vandetanib profile page.

Drug patent expirations by year for CAPRELSA
Generic Entry Opportunity Date for CAPRELSA
Generic Entry Date for CAPRELSA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for CAPRELSA
(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine
2ivu
338992-00-0
4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline
4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline
4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE
4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-
443913-73-3
68541-EP2298768A1
68541-EP2308855A1
913V733
A25648
AB0008635
AB01273969_04
AB01273969-01
AB01273969-02
AB1008463
ABP000873
AC-5251
AC1MIWRU
AJ-45811
AK106976
AKOS015902350
AN-3469
ANW-61824
AOB87780
AS-11067
AZD-6474
BC224441
BCPP000023
BDBM21
C22H24BrFN4O2
Caprelsa (TN)
CAS-443913-73-3
CH 331
CH-331
CHEBI:49960
CHEMBL24828
cid_3081361
CS-0130
CTK8B9016
D06407
D0G6QF
DB05294
DMPC Cyclic Urea 1
DSSTox_CID_26681
DSSTox_GSID_46681
DSSTox_RID_81816
DTXSID1046681
EN002713
EX-A422
F9995-0087
FT-0656736
GNF-PF-2188
GTPL5717
HE069787
HE343618
HMS3244K03
HMS3244K04
HMS3244L03
HMS3654E11
HSDB 8198
HY-10260
I14-1942
KB-34269
Kinome_3316
LS-184394
MCULE-4705827953
MFCD07772346
MLS006011672
MolPort-005-942-399
N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
NCGC00167513-01
NCGC00167513-02
NCGC00167513-03
NCGC00167513-04
NSC-744325
NSC-760766
NSC744325
NSC760766
PubChem22460
QCR-37
Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
RS0036
RT-016214
s1046
SC-23330
SCHEMBL9044
SMR002530472
SR-00000000462
SR-00000000462-2
ST2407381
SYN1090
Tox21_112511
Tox21_112511_1
UHTHHESEBZOYNR-UHFFFAOYSA-N
UNII-YO460OQ37K
V-9402
Vandetanib
Vandetanib (JAN/INN)
Vandetanib (JAN/USAN/INN)
Vandetanib (Pan-TK inhibitor)
vandetanib (zd6474)
Vandetanib [INN]
Vandetanib [USAN:INN:BAN:JAN]
Vandetanib, Zactima, ZD6474
Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine
Vandetanib(Zactima),ZD6474/
Vandetinib
W-5356
YO460OQ37K
Zactima
Zactima, ZD6474
ZD 6474
ZD-64
ZD-6474
ZD6474
ZINC53683345

US Patents and Regulatory Information for CAPRELSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for CAPRELSA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-001 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Genzyme Corp CAPRELSA vandetanib TABLET;ORAL 022405-002 Apr 6, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for CAPRELSA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/036 United Kingdom ➤ Try a Free Trial PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
2012000057 Germany ➤ Try a Free Trial PRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
1244647/01 Switzerland ➤ Try a Free Trial FORMER OWNER: ASTRAZENECA AB, SE
00543 Netherlands ➤ Try a Free Trial PRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
057 Luxembourg ➤ Try a Free Trial 92057, EXPIRES: 20251101
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Dow
Cantor Fitzgerald
McKinsey
QuintilesIMS
Chinese Patent Office
Queensland Health
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.